Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Descriptor ID |
D011993
|
MeSH Number(s) |
D12.776.828.300
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 7 | 25 | 32 |
1995 | 11 | 26 | 37 |
1996 | 7 | 28 | 35 |
1997 | 2 | 46 | 48 |
1998 | 2 | 37 | 39 |
1999 | 2 | 29 | 31 |
2000 | 5 | 50 | 55 |
2001 | 5 | 30 | 35 |
2002 | 12 | 41 | 53 |
2003 | 9 | 47 | 56 |
2004 | 9 | 60 | 69 |
2005 | 7 | 47 | 54 |
2006 | 7 | 42 | 49 |
2007 | 5 | 34 | 39 |
2008 | 6 | 24 | 30 |
2009 | 8 | 50 | 58 |
2010 | 10 | 27 | 37 |
2011 | 18 | 29 | 47 |
2012 | 8 | 18 | 26 |
2013 | 5 | 19 | 24 |
2014 | 14 | 18 | 32 |
2015 | 9 | 9 | 18 |
2016 | 7 | 15 | 22 |
2017 | 12 | 15 | 27 |
2018 | 8 | 9 | 17 |
2019 | 10 | 5 | 15 |
2020 | 16 | 5 | 21 |
2021 | 5 | 10 | 15 |
2022 | 2 | 15 | 17 |
2023 | 2 | 9 | 11 |
2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
-
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 Mar 23; 403(10432):1153-1163.
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
-
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602.
-
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med. 2024 Feb; 13(3):e6877.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2023 Dec 14; 389(24):2256-2266.
-
Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial. Ophthalmol Retina. 2024 Feb; 8(2):116-125.
-
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023 09 01; 141(9):834-842.
-
Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis. Vaccine. 2023 08 23; 41(37):5400-5411.